PharmaCielo Ltd.
PCLOF
$0.07
$0.0250.93%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 516.70K | 434.80K | 645.50K | 233.10K | -46.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 516.70K | 434.80K | 645.50K | 233.10K | -46.10K |
| Cost of Revenue | 316.20K | -285.20K | 1.01M | 277.00K | 480.50K |
| Gross Profit | 200.50K | 720.00K | -360.60K | -43.90K | -526.60K |
| SG&A Expenses | 490.80K | 230.60K | 1.56M | 600.90K | 656.00K |
| Depreciation & Amortization | 5.70K | 2.90K | 35.30K | 14.50K | 47.30K |
| Other Operating Expenses | 708.50K | -653.80K | -33.40K | -128.60K | 19.20K |
| Total Operating Expenses | 1.52M | -705.50K | 2.57M | 763.80K | 1.20M |
| Operating Income | -1.00M | 1.14M | -1.92M | -530.70K | -1.25M |
| Income Before Tax | -933.50K | 292.20K | -1.01M | -940.30K | -1.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -933.50K | 292.20K | -1.01M | -940.30K | -1.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -933.50K | 292.20K | -1.01M | -940.30K | -1.65M |
| EBIT | -1.00M | 1.14M | -1.92M | -530.70K | -1.25M |
| EBITDA | -385.40K | 1.45M | -1.86M | -516.20K | -948.50K |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 189.98M | 187.98M | 187.98M | 187.98M | 184.41M |
| Average Diluted Shares Outstanding | 189.98M | 187.98M | 187.98M | 187.98M | 184.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |